Hydrochloric Acid

Hydrochloric Acid

SCHEMBL4887069

Cl.Cl.c1cnnnn1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1724440 1.00
Hydrochloric Acid SCHEMBL2411891 1.00
Hydrochloric Acid SCHEMBL8841269 1.00
Hydrochloric Acid SCHEMBL27301644 0.95
SCHEMBL32662715 0.94
Charcoal, Activated SCHEMBL30186803 0.94
SCHEMBL51586 0.94
SCHEMBL28462068 0.94
Bromide SCHEMBL4559985 0.89
Methane SCHEMBL10400168 0.89

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113145857-A Copper-silver-tin ternary core-shell nano material and preparation method and application thereof 广东工业大学 2021-07-23 CN claimed
EP-2500018-A1 Preventing and/or Treating Cardiovascular Disease and/or Associated Heart Failure PhilERA New Zealand Limited (NZ) 2012-09-19 EP claimed
EP-1786363-A4 MEDICAL DEVICES HAVING NANOPOROUS LAYERS AND METHODS FOR MAKING THE SAME SETAGON INC (US) 2008-04-23 EP claimed
JP-2008509742-A 2008-04-03 JP claimed
EP-1786363-A2 MEDICAL DEVICES HAVING NANOPOROUS LAYERS AND METHODS FOR MAKING THE SAME Setagon, Inc. (US) 2007-05-23 EP claimed
WO-2006020742-A2 MEDICAL DEVICES HAVING NANOPOROUS LAYERS AND METHODS FOR MAKING THE SAME SETAGON, INC. (US) 2006-02-23 WO claimed
EP-1585506-A1 METHODS AND COMPOSITIONS FOR WOUND MANAGEMENT THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2005-10-19 EP claimed
WO-2004056346-A1 METHODS AND COMPOSITIONS FOR WOUND MANAGEMENT UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2004-07-08 WO claimed
JP-1244704-A None JP disclosed
CN-113145857-A Copper-silver-tin ternary core-shell nano material and preparation method and application thereof 广东工业大学 2021-07-23 CN disclosed
CN-101646762-A High surface area culture system with surface area enhancing substrate CINV AG DE 2010-02-10 CN disclosed
EP-1786363-A4 MEDICAL DEVICES HAVING NANOPOROUS LAYERS AND METHODS FOR MAKING THE SAME SETAGON INC (US) 2008-04-23 EP disclosed
WO-2007143433-A1 NANOPOROUS STENTS WITH ENHANCED CELLULAR ADHESION AND REDUCED NEOINTIMAL FORMATION SETAGON, INC. (US) 2007-12-13 WO disclosed
EP-1786363-A2 MEDICAL DEVICES HAVING NANOPOROUS LAYERS AND METHODS FOR MAKING THE SAME Setagon, Inc. (US) 2007-05-23 EP disclosed
CN-1688301-A Dosage forms and related therapies PROTEMIX CORP LTD (NZ) 2005-10-26 CN disclosed
EP-0797650-A1 PROCESS FOR THE ISOMERISATION OF A HYDROCARBONACEOUS FEEDSTOCK SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1997-10-01 EP disclosed
WO-1996018705-A1 PROCESS FOR THE ISOMERISATION OF A HYDROCARBONACEOUS FEEDSTOCK SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 1996-06-20 WO disclosed
CN-1024665-C process for preparing ring-substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes LILLY CO ELI (US) 1994-05-25 CN disclosed
CN-1038644-A Nuclear substituted 2-amino-1,2,3,4-tetralin class LILLY CO ELI (US) 1990-01-10 CN disclosed
JP-H01244704-A BLACK PEARL AND ITS PRODUCTION SHIMURA TADAMASA 1989-09-29 JP disclosed